Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally
Issues relating to biologics and biosimilars in Medicare and generally.
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Monitor legislative proposals relating to data privacy and security
Duration: January 1, 2020
to
present
General Issues: Medicare/Medicaid , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code , Consumer Issues/Safety/Protection
Spending: about $1,020,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2020: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Charles Brain Asst. to the President, Dp.Chief Staff W&M Cmte
Asst. to the President, Dp.Chief Staff W&M Cmte
A.J. Wojciak Senior Legislative Asst., Cong. Earl Pomeroy
Senior Legislative Asst., Cong. Earl Pomeroy
Tom Nagle Chief of Staff, U.S. Senator Tom Udall; Chief of Staff, U.S. Representative Tom Udall; Associate Staff, U.S. House Committee on Appropriations
Chief of Staff, U.S. Senator Tom Udall; Chief of Staff, U.S. Representative Tom Udall; Associate Staff, U.S. House Committee on Appropriations
Steve Eichenauer Legislative Assistant, U.S. Senator Jack Reed
Legislative Assistant, U.S. Senator Jack Reed
Abbie Sorrendino Chief of Staff, Office of Congressman Joe Morelle
Patrick O'Neill n/a
Nancy O'Neall n/a
Becca Durr n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on April 18.
Original Filing: 301553641.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor legislative proposals relating to data privacy and security
Agencies Lobbied
U.S. Senate
Type of Issue
Consumer Issues/Safety/Protection
4th Quarter, 2023
In Q4, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Jan. 22.
Original Filing: 301537987.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor legislative proposals relating to data privacy and security
Agencies Lobbied
U.S. Senate
Type of Issue
Consumer Issues/Safety/Protection
3rd Quarter, 2023
In Q3, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Oct. 20, 2023.
Original Filing: 301511199.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor legislative proposals relating to data privacy and security
Agencies Lobbied
U.S. Senate
Type of Issue
Consumer Issues/Safety/Protection
2nd Quarter, 2023
In Q2, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on July 19, 2023.
Original Filing: 301481412.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor legislative proposals relating to data privacy and security
Agencies Lobbied
U.S. Senate
Type of Issue
Consumer Issues/Safety/Protection
1st Quarter, 2023
In Q1, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on April 11, 2023.
Original Filing: 301450442.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor legislative proposals relating to data privacy and security
Agencies Lobbied
U.S. Senate
Type of Issue
Consumer Issues/Safety/Protection
4th Quarter, 2022
In Q4, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Jan. 18, 2023.
Original Filing: 301430503.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor legislative proposals related to data privacy and security
Agencies Lobbied
U.S. Senate
Type of Issue
Consumer Issues/Safety/Protection
3rd Quarter, 2022
In Q3, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Oct. 20, 2022.
Original Filing: 301415825.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals (H.R. 3)
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor legislative proposals related to data privacy and security
Agencies Lobbied
U.S. Senate
Type of Issue
Consumer Issues/Safety/Protection
2nd Quarter, 2022
In Q2, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on July 20, 2022.
Original Filing: 301391467.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals (H.R. 3)
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor legislative proposals related to data privacy and security
Agencies Lobbied
U.S. Senate
Type of Issue
Consumer Issues/Safety/Protection
1st Quarter, 2022
In Q1, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on April 20, 2022.
Original Filing: 301368742.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals (H.R. 3)
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Ongoing monitoring of the consideration of the Build Back Better Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2021
In Q4, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Jan. 19, 2022.
Original Filing: 301329160.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals (H.R. 3)
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Ongoing monitoring of the consideration of the Build Back Better Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2021
In Q3, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Oct. 20, 2021.
Original Filing: 301309204.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals (H.R. 3)
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Ongoing monitoring of the consideration of the Build Back Better Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2021
In Q2, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on July 20, 2021.
Original Filing: 301286453.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals (H.R. 3)
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Ongoing monitoring of the consideration of the American Jobs Plan.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2021
In Q1, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on April 20, 2021.
Original Filing: 301265013.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals.
Issues relating to biologics and biosimilars in Medicare and generally.
Provisions in the American Rescue Plan relating to pharmaceutical supply chain, vaccine and therapeutic development/reimbursement, home care reimbursement, and antimicrobial development incentives.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Ongoing monitoring of the consideration and implementation of the American Rescue Plan.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2020
In Q4, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Jan. 19, 2021.
Original Filing: 301235392.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals.
Issues relating to biologics and biosimilars in Medicare and generally.
Provisions in COVID-19 recovery packages relating to pharmaceutical supply chain, vaccine and therapeutic development/reimbursement, home care reimbursement, and antimicrobial development incentives.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Monitoring legislative proposals relating to, and implementation of, COVID-19 economic relief.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2020
In Q3, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Oct. 19, 2020.
Original Filing: 301215947.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals.
Issues relating to biologics and biosimilars in Medicare and generally.
Provisions in COVID-19 recovery packages relating to pharmaceutical supply chain, vaccine and therapeutic development/reimbursement, home care reimbursement, and antimicrobial development incentives.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Issues relating to COVID-19 economic relief.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2020
In Q2, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on July 17, 2020.
Original Filing: 301190941.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals.
Issues relating to biologics and biosimilars in Medicare and generally.
Provisions in COVID-19 recovery packages relating to pharmaceutical supply chain, vaccine and therapeutic development/reimbursement, home care reimbursement, and antimicrobial development incentives.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Issues relating to COVID-19 economic relief.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2020
In Q1, PUBLIC STRATEGIES WASHINGTON, INC. lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on April 17, 2020.
Original Filing: 301170863.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals.
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Issues relating to COVID-19 economic relief
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2020
Public Strategies Washington, Inc. filed a lobbying registration on Jan. 16, 2020 to represent BIOTECHNOLOGY INDUSTRY ORGANIZATION, effective Jan. 1, 2020.
Original Filing: 301107813.xml
Issue(s) they said they’d lobby about: Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals.
Issues relating to biologics and biosimilars in Medicare and generally.
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...